Authors
Loading...
Review uncovers elevated liver cancer risk and viral reactivation risks during antiviral therapy in HBV-HCV coinfection, highlighting the need for screening.
Mavilia et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: